M. A. Cherian

This study shows that inhibiting heparanase increases heparan sulfate levels, enhancing eATP and chemotherapy response in TNBC cells.

The paper tests the in vivo efficacy of estrogen receptor β agonists combined with tamoxifen in endocrine-resistant breast cancer models, finding no tumor volume reduction despite in vitro success.

This study shows that sulfatase 2 inhibition enhances chemotherapy effectiveness in TNBC by increasing extracellular ATP release and reducing cancer-initiating cells.

This study shows that selective ERβ agonists reduce viability of ER+ breast cancer cells and suggest their potential as a therapeutic strategy when combined with ER blockade.

This study shows that increasing extracellular ATP through P2RX channels and inhibiting ATPases enhances chemotherapy effectiveness in triple-negative breast cancer cells.